Lubomir Bodnar

BELLA: A phase 2 study of relacorilant plus nab-paclitaxel +/− bevacizumab in patients with gynecologic cancers

Jae-Weon Kim, Domenica Lorusso, Bradley Monk, Jeong-Yeol Park et autres

kr, us, it, fr, be, es, de, pl (code pays fourni par la source)

PARP Inhibitors and the Risk of Serum Creatinine Elevation in Ovarian Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Agnieszka Gąsowska-Bodnar, Beata Gąsowska-Bajger, Aleksandra Żołnierek, Jakub Żołnierek et autres

pl (code pays fourni par la source)

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer

Sara A. Hurvitz, Rachel M. Layman, Giuseppe Curigliano, Fabrice André et autres

us, it, fr, kr, mx, ar, au, lu, es, gb (code pays fourni par la source)

Real-World Outcomes of Primary Versus Interval Debulking Surgery in a Multicenter Cohort of Advanced Ovarian Cancer Patients Treated with Bevacizumab

Kaja Michalczyk, Lubomir Bodnar, Marta Czeluścińska-Murawiec, Anna Dańska-Bidzińska et autres

pl, hu (code pays fourni par la source)

Neoadjuvant chemotherapy of node-positive M0 urothelial bladder cancer.

Mateusz Malik, Maciej Różycki, Zbyszko Chowaniec, Jacek Ornat et autres

pl, it (code pays fourni par la source)

Subgroup analysis of tumour response by number and type of prior therapy in REJOICE-ovarian01, a phase 2 study of raludotatug deruxtecan (R-dxd) in patients with platinum-resistant ovarian cancer

Isabelle Ray-Coquard, Kosei Hasegawa, Giuseppe Caruso, Jung-Yun Lee et autres

fr, jp, it, kr, cz, cn, tw, pl, au, es, us (code pays fourni par la source)

Underuse of split-dose cisplatin in patients with moderate renal impairment may compromise optimal outcomes with avelumab maintenance in metastatic urothelial carcinoma: interim UROCAPOL registry data

Piotr J. Wysocki, Łukasz Kwinta, Anna Kostrzewska, Jakub Kucharz et autres

pl, us (code pays fourni par la source)

Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial

J. Randolph Hecht, Young Suk Park, Josep Tabernero, Myung Ah Lee et autres

us, kr, es, be, gb, au, nz, de, fr, pl (code pays fourni par la source)

Combination therapies with olaparib — new treatment options

Lubomir Bodnar, Radosław Mądry, Małgorzata Stawicka-Niełacna, Paweł Potocki

pl (code pays fourni par la source)

Selective inhibition of aminopeptidase N by paclitaxel: Insights into enzymatic interactions with cytostatics and analgesics in cancers

Małgorzata Pawełczak, Lubomir Bodnar, Beata Gąsowska-Bajger

pl (code pays fourni par la source)

Relacorilant and Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer (ROSELLA): An Open-label, Randomized, Controlled, Phase 3 Trial

Alexander Olawaiye, Laurence Gladieff, David M. O’Malley, Jae‐Weon Kim et autres

Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer

B.J. Rimel, Eric Pujade‐Lauraine, Kathleen Moore, Jacobus Pfisterer et autres

us, fr, de, be, cz, nl, es, gr, il, it, gb, dk, pl, ca, fi, Nigéria, jp (code pays fourni par la source)